Medical Sciences Correction for “Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis,” by Tao Liu, Andrew E. L. Tee, Antonio Porro, Stewart A. Smith, Tanya Dwarte, Pei Yan Liu, Nunzio Iraci, Eric Sekyere, Michelle Haber, Murray D. Norris, Daniel Diolaiti, Giuliano Della Valle, Giovanni Perini, and Glenn M. Marshall, which published November 20, 2007; 10.1073/pnas.0705524104 (Proc. Natl. Acad. Sci. U.S.A. 104, 18682–18687).
The authors note that the semiquantitative competitive RT-PCR and acrylamide gel electrophoresis result of N-Myc mRNA expression in BE(2)-C cells after transfection with control siRNA or N-Myc siRNA was mistakenly used for both BE(2)-C and IMR-32 cells in the Left panel of Fig. 2B on p. 18684. The erratum figure confirmed that transfection with N-Myc siRNA reduced N-Myc mRNA expression in both BE(2)-C and IMR-32 neuroblastoma cell lines. The corrected figure and its legend appear below. The online version has been corrected.
Fig. 2.
TG2 is transcriptionally repressed by N-Myc and c-Myc in neuroblastoma and breast cancer cells and activated by TSA in nonmalignant cells overexpressing N-Myc or c-Myc. (A) The effect of N-Myc on TG2 gene expression was examined by semiquantitative competitive RT-PCR of mRNA from N-Myc overexpressing SHEP S1 or empty vector control SHEP EV cells. (B) SHEP S1, BE(2)-C, and IMR-32 neuroblastoma cells were transfected with scrambled siRNA or siRNA specifically targeting N-Myc, followed by RNA extraction, and RT-PCR. (C) MCF-7 and MDA-MB-468 breast cancer cells were transfected with scrambled or c-Myc siRNA, followed by RNA extraction and RT-PCR. (D) Nonmalignant MRC-5 and HMEC cells were transfected with a control empty vector or a construct overexpressing c-Myc or N-Myc, respectively, and treated with control or TSA for 24 h. c-Myc, N-Myc, and TG2 expression was examined by RT-PCR.